1,3,4,9-tetrahydro-β-carboline-2,3-dicarboxylic acid 2-benzyl ester | 65491-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,3,4,9-tetrahydro-β-carboline-2,3-dicarboxylic acid 2-benzyl ester
• 英文别名: (3S)-2-benzyloxycarbonyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid；Z-Tpi-OH；(3S)-2-phenylmethoxycarbonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylic acid
• CAS: 65491-10-3
• 化学式: C₂₀H₁₈N₂O₄
• 分子量: 350.374
• InChiKey: JOMKLISBGHMKKW-SFHVURJKSA-N

物化性质

• 沸点：
  608.3±55.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  82.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,3,4,9-tetrahydro-β-carboline-2,3-dicarboxylic acid 2-benzyl ester 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 16.5h， 生成 (3S)-2-(methylthio)thiocarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-acetic acid
  参考文献：
  名称：

  Synthesis of 1,2,3,4-tetrahydro-.BETA.-carboline derivatives as hepatoprotective agents. III. Introduction of substituents onto methyl 1,2,3,4-tetrahydro-.BETA.-carboline-2-carbodithioate.

  摘要：

  合成了多种取代四氢-β-吲哚-二硫代氨基甲酸盐，并测试了其在小鼠中对四氯化碳 (CCl4) 诱导的肝损伤的肝保护活性。研究了结构-活性关系。3位取代基与二硫代氨基甲酸盐基团的相邻基团参与似乎对活性的体现非常重要。在3位具有亲水性取代基的化合物（1a、2a 和 3i）表现出了显著的活性。在3-羧酸（1a）的9位进行取代则降低了活性。

  DOI：

  10.1248/cpb.35.3284
• 作为产物：
  描述：

  methyl (3S)-1,2,3,4-tetrahydro-β-carboline-3-carboxylate 在 sodium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1,3,4,9-tetrahydro-β-carboline-2,3-dicarboxylic acid 2-benzyl ester
  参考文献：
  名称：

  Synthesis, molecular modeling and QSAR studies in chiral 2,3-disubstituted-1,2,3,4-tetrahydro-9H-pyrido(3,4-b)indoles as potential modulators of opioid antinociception

  摘要：

  In view of coexistence of opioid and cholecystokinin (CCK) in the brain areas concerned with pain processing, some semirigid racemic and chiral analogues of a potent CCK receptor antagonist (benzotript) have been synthesized and tested for their modulatory role on opioid antinociception, which may be mediated by CCK-B receptor. Some of these compounds, 3e, 3g, 3h, 4a, 4b and 4h, exhibited antinociceptive potentiation comparable to benzotript and proglumide. In order to identify the essential chemical structural features important for this potentiation, molecular modeling and quantitative structure activity relationship (QSAR) studies have been carried out in the S and R enantiomers of some of these semi-rigid compounds. The 3D-biophore models, common to all molecules of the training set have been derived. These models with superimposition (match value > 0.25) depicted three biophoric sites one each for, pi /hydrophobic interactions, hydrogen bonding and ionic interactions among the phenyl/pyrrole ring, indole nitrogen, amidic oxygen, pyridyl nitrogen and lone pair of amidic oxygen. The total hydrophobicity and S absolute stereochemistry are found to positively contribute to potentiation of antinociception induced by morphine and the resulting quantitative pharmacophoric model with good correlation is found to well describe the observed activity. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00042-6

文献信息

• Tetrahydro-.beta.-carboline derivatives and treatment of liver diseases
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04628057A1

  公开（公告）日：1986-12-09

  Novel tetrahydro-.beta.-carboline derivatives of the formula: ##STR1## wherein R.sup.1 is carboxyl, a lower alkoxycarbonyl, carbamoyl, an N,N-di-lower alkylcarbamoyl, an N-(phenyl-substituted lower alkylidenamino)carbamoyl, a [N,N-di(lower alkyl)amino]-lower alkyl, or a nitrogen-containing monocyclic heterocyclic group; R.sup.2 is hydrogen atom, a lower alkyl, or a hydroxy-lower alkyl group, or R.sup.2 is combined with R.sup.1 to form a group: --CO--O--CH.sub.2 --; R.sup.3 is hydrogen atom, a lower alkyl, a phenyl-lower alkyl, or a group: --CSS--R.sup.4 ; R.sup.4 is hydrogen atom, an alkyl, or a group: --(CH.sub.2).sub.n Y.sup.1 ; n is 0, 1 or 2, Y.sup.1 is a lower alkenyl, a phenyl-substituted lower alkenyl, an N,N-di(lower alkyl)amino, a lower alkylmercapto, a lower alkoxycarbonyl, benzoyl, naphthyl, a cycloalkyl, a monocyclic heterocyclic group, or a substituted or unsubstituted phenyl, which have excellent activities for alleviating, curing and preventing hepatic damages and are useful as a therapeutic or prophylactic agent for hepatic diseases, and processes for the preparation thereof, and a pharmaceutical composition containing the above compound as an active ingredient.

  该专利描述了一种新型的四氢-β-咔啉衍生物，其化学式为：##STR1## 其中R.sup.1为羧基、较低的烷氧羰基、氨基甲酰基、N,N-二较低烷基氨基甲酰基、N-(苯基取代的较低烷基亚氨基)甲酰基、[N,N-二(较低烷基)氨基]-较低烷基，或含氮的单环杂环基团；R.sup.2为氢原子、较低的烷基，或羟基较低烷基基团，或R.sup.2与R.sup.1结合形成一个基团：--CO--O--CH.sub.2 --；R.sup.3为氢原子、较低的烷基、苯基较低烷基，或一个基团：--CSS--R.sup.4；R.sup.4为氢原子、烷基，或一个基团：--(CH.sub.2).sub.n Y.sup.1；n为0、1或2，Y.sup.1为较低烯基、苯基取代的较低烯基、N,N-二(较低烷基)氨基、较低烷基硫醇基、较低的烷氧羰基、苯甲酰基、萘基、环烷基、单环杂环基团，或取代或未取代的苯基，这些化合物对缓解、治愈和预防肝损伤具有出色的活性，并可用作治疗或预防肝病的药物，以及其制备方法和含有上述化合物作为活性成分的药物组合物。
• Tetrahydro-beta-carboline derivatives and process for the preparation thereof
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0145304A1

  公开（公告）日：1985-06-19

  Novel tetrahydro-β-carboline derivatives of the formula: wherein R' is carboxyl, a lower alkoxycarbonyl, carbamoyl, an N,N-di-lower alkylcarbamoyl, an N-(phenyl-substituted lower alkylidenamino)carbamoyl, a [N,N-di(lower alkyl)-amino]-lower alkyl, or a nitrogen-containing monocyclic heterocyclic group; R2 is hydrogen atom, a lower alkyl, or a hydroxy-lower alkyl group, or R2 is combined with R' to form a group: -CO-0-CH2-; R3 is hydrogen atom, a lower alkyl, a phenyl-lower alkyl, or a group: -CSS-R4; R4 is hydrogen atom, an alkyl, or a group: -(CH2)nY1; n is 0, 1 or 2, Y1 is a lower alkenyl, a phenyl-substituted lower alkenyl, an N,N-di(lower alkyl)amino, a lower alkylmercapto, a lower alkoxycarbonyl, benzoyl, naphthyl, a cycloalkyl, a monocyclic heterocyclic group, or a substituted or unsubstituted phenyl, which have excellent activities for alleviating, curing and preventing hepatic damages and are useful as a therapeutic or prophylactic agent for hepatic diseases, and processes for the preparation thereof, and a pharmaceutical composition containing the above compound as an active ingredient.

  式中的新型四氢-β-咔啉衍生物： 其中 R' 是羧基、低级烷氧基羰基、氨基甲酰基、N,N-二低级烷基氨基甲酰基、N-（苯基取代的低级亚烷基氨基）氨基甲酰基、[N,N-二（低级烷基）-氨基]-低级烷基或含氮单环杂环基团； R2 是氢原子、低级烷基或羟基-低级烷基，或 R2 与 R' 结合形成一个基团：-CO-0-CH2-； R3 是氢原子、低级烷基、苯基-低级烷基或一个基团：-CSS-R4； R4 是氢原子、烷基或基团：-(CH2)nY1； n 是 0、1 或 2、 Y1 是低级烯基、苯基取代的低级烯基、N,N-二（低级烷基）氨基、低级烷基巯基、低级烷氧基羰基、苯甲酰基、萘基、环烷基、单环杂环基团或取代或未取代的苯基，它们在缓解、治疗和预防肝病方面具有极佳的活性、及其制备工艺，以及含有上述化合物作为活性成分的药物组合物。
• SAIGA, YUTAKA;IIJIMA, IKUO;ISHIDA, AKIHIKO;MIYAGISHIMA, TOSHIKAZU;HOMMA, +, CHEM. AND PHARM. BULL., 35,(1987) N 8, 3284-3291
  作者：SAIGA, YUTAKA、IIJIMA, IKUO、ISHIDA, AKIHIKO、MIYAGISHIMA, TOSHIKAZU、HOMMA, +

  DOI：——

  日期：——
• TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS
  申请人：RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.

  公开号：EP0491943A1

  公开（公告）日：1992-07-01
• EP0491943A4
  申请人：——

  公开号：EP0491943A4

  公开（公告）日：1996-02-14